Vertex Pharma (VRTX) Tops Q4 EPS by 13c, offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $549.04 --0%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
KEEL, SENEA, XFOR, More
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
KEEL, SENEA, XFOR, More
Join SI Premium – FREE
(Updated - February 5, 2024 4:49 PM EST)
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $4.20, $0.13 better than the analyst estimate of $4.07. Revenue for the quarter came in at $2.52 billion versus the consensus estimate of $2.51 billion.
GUIDANCE:
Vertex Pharma sees Q1 2024 revenue of $10.55-10.75 billion, versus the consensus of $10.61 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Appian Corporation (APPN) Tops Q3 EPS by 18c; Offers Guidance
- Arrow Electronics (ARW) Tops Q3 EPS by 147c ; Offers Guidance
- Nextdoor Holdings, Inc. (NXDR) reported Q3 Revenue ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
